KRTL Holding Group Announces RAYEL and PERIKO Coca-Derived Extract Platform for Beverage and Pharmaceutical API Development
https://www.globenewswire.com/news-release/20...pment.html
Lakewood, CO, June 18, 2026 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) today announced the creation and strategic alignment of two coca-derived extract assets, RAYEL and PERIKO, through its subsidiary-led platform involving KRTL Biotech Inc., KRTL International Corp., and partnered with Centro de Investigaciones Químicas S.R.L. (“CIQ”).
The Company believes this milestone represents a meaningful step in the modern history of coca-derived botanical development. For more than a century, coca has occupied a unique place in beverage history, most famously through early botanical beverage formulations that helped shape the global soft drink category. Today, KRTL is working to advance that legacy through a documented, compliance-focused platform designed for modern beverage, nutraceutical, and pharmaceutical/API opportunities.
RAYEL is KRTL’s near-term commercial beverage asset. Based on Company records, RAYEL has been the subject of Alcohol and Tobacco Tax and Trade Bureau (“TTB”) approval within a documented product scope for use in alcoholic beverage applications. The Company believes this documentation may support a regulated pathway for partner discussions, product-scope review, formula and label review, state distribution analysis, and potential licensing or commercialization opportunities.
PERIKO is being positioned separately as a development-stage pharmaceutical/API pathway. While RAYEL is focused on the beverage market, PERIKO is intended to support longer-term scientific, regulatory, and partner-development work involving coca-derived active-ingredient opportunities. PERIKO is not an approved drug, API, therapeutic product, dietary supplement or commercial beverage product.
“RAYEL and PERIKO represent more than two extracts — they represent the foundation of a modern coca-derived innovation platform,” said Cesar Herrera, Chief Executive Officer of KRTL Holding Group Inc. “RAYEL gives us a TTB-approved commercial beverage pathway, while PERIKO gives us a separate development lane for pharmaceutical and API exploration. Together with CIQ, we believe this creates a rare opportunity to bring history, science, and modern compliance together in a disciplined commercial framework.”
The Company’s current strategy is to align RAYEL and PERIKO through a phased commercialization and development plan. For RAYEL, KRTL intends to focus on beverage-industry commercialization, including qualified formulation partners, licensed operators, brand-development opportunities, distributor discussions, and potential licensing or joint-venture structures. For PERIKO, the Company intends to organize rights documentation, technical summaries, regulatory pathway analysis, and qualified pharmaceutical/API partner review.
The Company’s intended activities are limited to lawful, documented, decocainized coca-derived materials and extracts that do not contain cocaine or ecgonine, and any commercial activity remains subject to applicable regulatory, import, manufacturing, formulation, labeling, distribution, and controlled-substance review.
CIQ is expected to support the platform through scientific collaboration, Bolivia-facing research coordination, technical documentation, and applied chemistry expertise, subject to written agreements, confidentiality controls, data-use permissions, and applicable approvals.
“This is the type of milestone that connects cultural history with modern regulated product development,” added Herrera. “The goal is not to overstate the opportunity. The goal is to do it correctly — with the right records, the right partners, the right regulatory review, and the right commercial discipline.”
KRTL expects RAYEL to serve as the first commercial anchor for the platform. The Company is preparing a commercialization package that may include TTB approval records, product-scope materials, claims guidelines, partner materials, state-market review, supply-chain review, and commercial term frameworks. The Company also intends to evaluate future nutraceutical, functional ingredient, and API opportunities where lawful, documented, and commercially appropriate.
The Company notes that RAYEL’s TTB approval applies only within the documented product scope and does not by itself constitute FDA approval, DEA approval, state distribution approval, customs clearance, therapeutic authorization, or approval of any health, wellness, or medical claim. Any regulated handling, importation, distribution, formulation, manufacturing, or commercialization activity will require appropriate partners, registrations, permits, legal review, and applicable approvals.
https://www.globenewswire.com/news-release/20...pment.html
Lakewood, CO, June 18, 2026 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) today announced the creation and strategic alignment of two coca-derived extract assets, RAYEL and PERIKO, through its subsidiary-led platform involving KRTL Biotech Inc., KRTL International Corp., and partnered with Centro de Investigaciones Químicas S.R.L. (“CIQ”).
The Company believes this milestone represents a meaningful step in the modern history of coca-derived botanical development. For more than a century, coca has occupied a unique place in beverage history, most famously through early botanical beverage formulations that helped shape the global soft drink category. Today, KRTL is working to advance that legacy through a documented, compliance-focused platform designed for modern beverage, nutraceutical, and pharmaceutical/API opportunities.
RAYEL is KRTL’s near-term commercial beverage asset. Based on Company records, RAYEL has been the subject of Alcohol and Tobacco Tax and Trade Bureau (“TTB”) approval within a documented product scope for use in alcoholic beverage applications. The Company believes this documentation may support a regulated pathway for partner discussions, product-scope review, formula and label review, state distribution analysis, and potential licensing or commercialization opportunities.
PERIKO is being positioned separately as a development-stage pharmaceutical/API pathway. While RAYEL is focused on the beverage market, PERIKO is intended to support longer-term scientific, regulatory, and partner-development work involving coca-derived active-ingredient opportunities. PERIKO is not an approved drug, API, therapeutic product, dietary supplement or commercial beverage product.
“RAYEL and PERIKO represent more than two extracts — they represent the foundation of a modern coca-derived innovation platform,” said Cesar Herrera, Chief Executive Officer of KRTL Holding Group Inc. “RAYEL gives us a TTB-approved commercial beverage pathway, while PERIKO gives us a separate development lane for pharmaceutical and API exploration. Together with CIQ, we believe this creates a rare opportunity to bring history, science, and modern compliance together in a disciplined commercial framework.”
The Company’s current strategy is to align RAYEL and PERIKO through a phased commercialization and development plan. For RAYEL, KRTL intends to focus on beverage-industry commercialization, including qualified formulation partners, licensed operators, brand-development opportunities, distributor discussions, and potential licensing or joint-venture structures. For PERIKO, the Company intends to organize rights documentation, technical summaries, regulatory pathway analysis, and qualified pharmaceutical/API partner review.
The Company’s intended activities are limited to lawful, documented, decocainized coca-derived materials and extracts that do not contain cocaine or ecgonine, and any commercial activity remains subject to applicable regulatory, import, manufacturing, formulation, labeling, distribution, and controlled-substance review.
CIQ is expected to support the platform through scientific collaboration, Bolivia-facing research coordination, technical documentation, and applied chemistry expertise, subject to written agreements, confidentiality controls, data-use permissions, and applicable approvals.
“This is the type of milestone that connects cultural history with modern regulated product development,” added Herrera. “The goal is not to overstate the opportunity. The goal is to do it correctly — with the right records, the right partners, the right regulatory review, and the right commercial discipline.”
KRTL expects RAYEL to serve as the first commercial anchor for the platform. The Company is preparing a commercialization package that may include TTB approval records, product-scope materials, claims guidelines, partner materials, state-market review, supply-chain review, and commercial term frameworks. The Company also intends to evaluate future nutraceutical, functional ingredient, and API opportunities where lawful, documented, and commercially appropriate.
The Company notes that RAYEL’s TTB approval applies only within the documented product scope and does not by itself constitute FDA approval, DEA approval, state distribution approval, customs clearance, therapeutic authorization, or approval of any health, wellness, or medical claim. Any regulated handling, importation, distribution, formulation, manufacturing, or commercialization activity will require appropriate partners, registrations, permits, legal review, and applicable approvals.
